Some analysts are betting Pfizer Inc. won’t have to withdraw its arthritis drug Celebrex but they do expect sales to fall after a study of the drug in cancer patients showed it increased the risk of heart attacks. Pfizer has said it has no plans to withdraw Celebrex, which had annual sales of nearly $2 billion last year. The U.S. Food and Drug Administration, which on Friday urged doctors to consider prescribing alternatives to Celebrex, plans to make additional announcements about the drug over the next few days.
